IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.462
AS - Asia 2.473
EU - Europa 1.864
SA - Sud America 347
AF - Africa 172
Continente sconosciuto - Info sul continente non disponibili 131
OC - Oceania 2
Totale 8.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.336
SG - Singapore 856
CN - Cina 601
VN - Vietnam 437
IT - Italia 407
SE - Svezia 336
IE - Irlanda 291
BR - Brasile 246
DE - Germania 184
HK - Hong Kong 178
FR - Francia 139
ZA - Sudafrica 107
BD - Bangladesh 102
TR - Turchia 85
FI - Finlandia 83
NL - Olanda 83
CA - Canada 78
GB - Regno Unito 74
AT - Austria 62
IN - India 43
RU - Federazione Russa 42
AR - Argentina 32
JP - Giappone 23
CZ - Repubblica Ceca 22
RO - Romania 22
BE - Belgio 20
IQ - Iraq 20
MX - Messico 20
CI - Costa d'Avorio 19
ES - Italia 19
PL - Polonia 18
TH - Thailandia 16
ID - Indonesia 15
CO - Colombia 14
EC - Ecuador 14
PH - Filippine 14
PK - Pakistan 14
UA - Ucraina 14
VE - Venezuela 13
LT - Lituania 11
CL - Cile 10
PY - Paraguay 10
KR - Corea 9
KE - Kenya 8
MA - Marocco 8
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CR - Costa Rica 6
ET - Etiopia 6
EU - Europa 6
UZ - Uzbekistan 6
EG - Egitto 5
IL - Israele 5
TW - Taiwan 5
JM - Giamaica 4
KH - Cambogia 4
PE - Perù 4
SC - Seychelles 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
EE - Estonia 3
HN - Honduras 3
IR - Iran 3
JO - Giordania 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
NP - Nepal 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
TN - Tunisia 3
BZ - Belize 2
DK - Danimarca 2
GT - Guatemala 2
MU - Mauritius 2
MZ - Mozambico 2
PR - Porto Rico 2
PT - Portogallo 2
SA - Arabia Saudita 2
SM - San Marino 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
Totale 8.313
Salva come PNG Salva come JPEG
Città #
Ashburn 513
Singapore 460
Chandler 333
San Jose 330
Dublin 286
Santa Clara 245
Hong Kong 171
Dallas 166
Parma 143
Ho Chi Minh City 136
Beijing 120
New York 103
Johannesburg 102
Hanoi 99
Los Angeles 98
Ann Arbor 93
Shanghai 92
Boardman 89
Council Bluffs 89
Dearborn 67
Munich 62
Vienna 57
Izmir 54
Lauterbourg 52
Nanjing 51
Princeton 45
Marseille 38
Buffalo 35
São Paulo 32
Toronto 29
Helsinki 28
Wilmington 27
Columbus 25
Milan 24
The Dalles 24
Bremen 23
Moscow 23
Shenyang 23
Turku 22
Orem 21
Tokyo 21
Abidjan 19
Da Nang 19
Brno 18
Brussels 18
Rome 17
Houston 16
Phoenix 16
Warsaw 16
Atlanta 15
Poplar 15
San Mateo 15
Frankfurt am Main 14
Hebei 14
Jinan 14
Kunming 14
Montreal 14
Düsseldorf 13
Hefei 13
London 13
Nanchang 13
Haiphong 12
Kocaeli 12
Modena 12
Amsterdam 11
Denver 11
Nuremberg 11
San Francisco 11
Stockholm 11
Ankara 10
Biên Hòa 10
Brooklyn 10
Chennai 10
Chicago 10
Focsani 10
Guangzhou 10
Jakarta 10
Redmond 10
Bologna 9
Dhaka 9
Newark 9
Bangkok 8
Changsha 8
Charlotte 8
Fairfield 8
Jiaxing 8
North Bergen 8
Ottawa 8
Washington 8
Woodbridge 8
Hải Dương 7
Madrid 7
Manchester 7
Norwalk 7
Pune 7
Seattle 7
Tianjin 7
Zhengzhou 7
Addis Ababa 6
Asunción 6
Totale 5.105
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 235
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 228
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 227
A simplified sars-cov-2 pseudovirus neutralization assay 223
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 206
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 206
Novel targets for the treatment of relapsing multiple myeloma 205
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 204
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 199
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 198
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 197
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 197
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 195
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 192
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 188
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 186
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 186
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 186
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 182
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 180
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 167
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 165
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 165
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 165
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 164
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 161
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 159
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 157
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 156
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 156
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 155
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 154
Oncolytic virotherapy and microenvironment in multiple myeloma 153
The impact of CD56 expression in smoldering myeloma patients on early progression 150
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 147
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 146
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 142
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 138
Possible targets to treat myeloma-related osteoclastogenesis 138
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 129
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 128
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 128
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 126
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 117
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 116
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 109
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 107
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 105
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 104
Role of Galectins in Multiple Myeloma. 104
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 100
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 92
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes 19
Use of bovine viruses as alternative tools in multiple myeloma oncolytic virotherapy 9
Totale 8.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.171
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.171
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022270 0 0 0 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/20251.531 27 60 84 140 162 142 106 87 194 119 144 266
2025/20263.257 318 244 362 301 469 201 341 111 400 276 133 101
2026/2027644 50 193 199 202 0 0 0 0 0 0 0 0
Totale 8.451